Can Machine Learning help us in dealing with treatment resistant depression? A review.


Journal

Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073

Informations de publication

Date de publication:
01 12 2019
Historique:
received: 13 05 2019
revised: 06 08 2019
accepted: 09 08 2019
pubmed: 23 8 2019
medline: 9 7 2020
entrez: 23 8 2019
Statut: ppublish

Résumé

About one third of patients treated with antidepressant do not show sufficient symptoms relief and up to 15% of patients remain symptomatic even after multiple trials are applied, configuring a state called treatment resistant depression (TRD). A clear definition of this state and the understanding of underlying mechanisms contributing to chronic disability caused by major depressive disorder is still unknown. Therefore, Machine Learning (ML) techniques emerged in the last years as interesting approaches to deal with such complex problems. We performed a bibliographic search on Pubmed, Google Scholar and Medline of clinical, imaging, genetic and EEG ML classification studies on treatment-responding depression and TRD as well as studies trying to predict response to a specific treatment in already established TRD. The inclusion criteria were met by eleven studies. Seven focused on the definition of predictors of TRD onset while four attempted to predict the response to specific treatments in TRD. The results showed that it seems possible to classify between responders MDD and TRD with good accuracies based on clinical variables. Moreover, some studies reported the possibility of using EEG measures to predict response to different pharmacological and non-pharmacological treatments in established TRD. The definition of TRD, the selection of variables together with ML algorithms and pipelines varies across the studies, ultimately determining the unfeasibility to implement these models in clinical practice. The findings suggest that ML could be a valid approach to increase our understanding of TRD and to better classify and stratify this disorder, which may ultimately help clinicians in the assessment of major depressive disorders.

Sections du résumé

BACKGROUND
About one third of patients treated with antidepressant do not show sufficient symptoms relief and up to 15% of patients remain symptomatic even after multiple trials are applied, configuring a state called treatment resistant depression (TRD). A clear definition of this state and the understanding of underlying mechanisms contributing to chronic disability caused by major depressive disorder is still unknown. Therefore, Machine Learning (ML) techniques emerged in the last years as interesting approaches to deal with such complex problems.
METHODS
We performed a bibliographic search on Pubmed, Google Scholar and Medline of clinical, imaging, genetic and EEG ML classification studies on treatment-responding depression and TRD as well as studies trying to predict response to a specific treatment in already established TRD. The inclusion criteria were met by eleven studies. Seven focused on the definition of predictors of TRD onset while four attempted to predict the response to specific treatments in TRD.
RESULTS
The results showed that it seems possible to classify between responders MDD and TRD with good accuracies based on clinical variables. Moreover, some studies reported the possibility of using EEG measures to predict response to different pharmacological and non-pharmacological treatments in established TRD.
LIMITATIONS
The definition of TRD, the selection of variables together with ML algorithms and pipelines varies across the studies, ultimately determining the unfeasibility to implement these models in clinical practice.
CONCLUSIONS
The findings suggest that ML could be a valid approach to increase our understanding of TRD and to better classify and stratify this disorder, which may ultimately help clinicians in the assessment of major depressive disorders.

Identifiants

pubmed: 31437696
pii: S0165-0327(19)31233-9
doi: 10.1016/j.jad.2019.08.009
pii:
doi:

Substances chimiques

Antidepressive Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

21-26

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

Alessandro Pigoni (A)

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Department of Neurosciences and Mental Health, Milan, Italy; University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy.

Giuseppe Delvecchio (G)

University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy.

Domenico Madonna (D)

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Department of Neurosciences and Mental Health, Milan, Italy; University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy.

Cinzia Bressi (C)

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Department of Neurosciences and Mental Health, Milan, Italy; University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy.

Jair Soares (J)

Department of Psychiatry and Behavioural Sciences, UT Houston Medical School, Houston, TX, USA.

Paolo Brambilla (P)

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Department of Neurosciences and Mental Health, Milan, Italy; University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy. Electronic address: paolo.brambilla1@unimi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH